Activation of the bile acid receptor TGR5 enhances LPS-induced inflammatory responses in a human monocytic cell line

References

• Steiner C, Othman A, Saely CH, et al. Bile acid metabolites in serum: intraindividual variation and associations with coronary heart disease, metabolic syndrome and diabetes mellitus. PLoS One 2011;6:e25006
   PubMed Web of Science ®Google Scholar
• Angelin B, Bjorkhem I, Einarsson K, Ewerth S. Hepatic uptake of bile acids in man. Fasting and postprandial concentrations of individual bile acids in portal venous and systemic blood serum. J Clin Invest 1982;70:724–31
   PubMed Web of Science ®Google Scholar
• Maruyama T, Miyamoto Y, Nakamura T, et al. Identification of membrane-type receptor for bile acids (M-BAR). Biochem Biophys Res Commun 2002;298:714–19
   PubMed Web of Science ®Google Scholar
• Keitel V, Cupisti K, Ullmer C, et al. The membrane-bound bile acid receptor TGR5 is localized in the epithelium of human gallbladders. Hepatology 2009;50:861–70
   PubMed Web of Science ®Google Scholar
• Kawamata Y, Fujii R, Hosoya M, et al. A G protein-coupled receptor responsive to bile acids. J Biol Chem 2003;278:9435–40
   PubMed Web of Science ®Google Scholar
• Watanabe M, Houten SM, Mataki C, et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 2006;439:484–9
   PubMed Web of Science ®Google Scholar
• Thomas C, Gioiello A, Noriega L, et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab 2009;10:167–77
   PubMed Web of Science ®Google Scholar
• Keitel V, Donner M, Winandy S, et al. Expression and function of the bile acid receptor TGR5 in Kupffer cells. Biochem Biophys Res Commun 2008;372:78–84
   PubMed Web of Science ®Google Scholar
• Pols TW, Nomura M, Harach T, et al. TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading. Cell Metab 2011;14:747–57
   PubMed Web of Science ®Google Scholar
• Ghoshal S, Witta J, Zhong J, et al. Chylomicrons promote intestinal absorption of lipopolysaccharides. J Lipid Res 2009;50:90–7
   PubMed Web of Science ®Google Scholar
• Neal MD, Leaphart C, Levy R, et al. Enterocyte TLR4 mediates phagocytosis and translocation of bacteria across the intestinal barrier. J Immunol 2006;176:3070–9
   PubMed Web of Science ®Google Scholar
• Jialal I, Huet BA, Kaur H, et al. Increased toll-like receptor activity in patients with metabolic syndrome. Diabetes Care 2012;35:900–4
   PubMed Web of Science ®Google Scholar
• Pussinen PJ, Havulinna AS, Lehto M, et al. Endotoxemia is associated with an increased risk of incident diabetes. Diabetes Care 2011;34:392–7
   PubMed Web of Science ®Google Scholar
• Tsukumo DM, Carvalho-Filho MA, Carvalheira JB, et al. Loss-of-function mutation in Toll-like receptor 4 prevents diet-induced obesity and insulin resistance. Diabetes 2007;56:1986–98
   PubMed Web of Science ®Google Scholar
• Kim F, Pham M, Luttrell I, et al. Toll-like receptor-4 mediates vascular inflammation and insulin resistance in diet-induced obesity. Circ Res 2007;100:1589–96
   PubMed Web of Science ®Google Scholar
• Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007;56:1761–72
   PubMed Web of Science ®Google Scholar
• Carlsen H, Moskaug JO, Fromm SH, Blomhoff R. In vivo imaging of NF-kappa B activity. J Immunol 2002;168:1441–6
   PubMed Web of Science ®Google Scholar
• Genet C, Strehle A, Schmidt C, et al. Structure–activity relationship study of betulinic acid, a novel and selective tgr5 agonist, and its synthetic derivatives: potential impact in diabetes. J Med Chem 2010;53:178–90
   PubMed Web of Science ®Google Scholar
• Yang JI, Yoon JH, Myung SJ, et al. Bile acid-induced TGR5-dependent c-Jun-N terminal kinase activation leads to enhanced caspase 8 activation in hepatocytes. Biochem Biophys Res Commun 2007;361:156–61
   PubMed Web of Science ®Google Scholar
• Yasuda H, Hirata S, Inoue K, et al. Involvment of membrane-type bile acid receptor M-BART/TGR5 in bile acid-induced activation of epidermal growth factor receptor and mitogen-activated protein kinases in gastric carcinoma cells. Biochem Biophys Res Commun 2006;354:154–9
   PubMed Web of Science ®Google Scholar
• Jin J, Samuvel DJ, Zhang X, et al. Coactivation of TLR4 and TLR2/6 coordinates an additive augmentation on IL-6 gene transcription via p38MAPK pathway in U937 mononuclear cells. Mol Immunol 2011;49:423–32
   PubMed Web of Science ®Google Scholar
• Wang YD, Chen WD, Yu D, et al. The G-protein-coupled bile acid receptor, Gpbar1 (TGR5), negatively regulates hepatic inflammatory response through antagonizing nuclear factor kappa light-chain enhancer of activated B cells (NF-kappaB) in mice. Hepatology 2011;54:1421–32
   PubMed Web of Science ®Google Scholar
• Thomas C, Pellicciari R, Pruzanski M, et al. Targeting bile-acid signalling for metabolic diseases. Nat Rev Drug Discov 2008;7:678–93
   PubMed Web of Science ®Google Scholar
• Jin J, Sundararaj KP, Samuvel DJ, et al. Different signaling mechanisms regulating IL-6 expression by LPS between gingival fibroblasts and mononuclear cells: seeking the common target. Clin Immunol 2012;143:188–99
   PubMed Web of Science ®Google Scholar
• Vermeulen L, De Wilde G, Van Damme P, et al. Transcriptional activation of the NF-kappaB p65 subunit by mitogen- and stress-activated protein kinase-1 (MSK1). EMBO J 2003;22:1313–24
   PubMed Web of Science ®Google Scholar
• Saha RN, Jana M, Pahan K. MAPK p38 regulates transcriptional activity of NF-kappaB in primary human astrocytes via acetylation of p65. J Immunol 2007;179:7101–9
   PubMed Web of Science ®Google Scholar
• Vanden Berghe W, Plaisance S, Boone E, et al. p38 and extracellular signal-regulated kinase mitogen-activated protein kinase pathways are required for nuclear factor-kappaB p65 transactivation mediated by tumor necrosis factor. J Biol Chem 1998;273:3285–90
   PubMed Web of Science ®Google Scholar
• Olson CM, Hedrick MN, Izadi H, et al. p38 mitogen-activated protein kinase controls NF-kappaB transcriptional activation and tumor necrosis factor alpha production through RelA phosphorylation mediated by mitogen- and stress-activated protein kinase 1 in response to Borrelia burgdorferi antigens. Infect Immun 2007;75:270–7
   PubMed Web of Science ®Google Scholar
• Stein B, Baldwin AS Jr, Ballard DW, et al. Cross-coupling of the NF-kappa B p65 and Fos/Jun transcription factors produces potentiated biological function. EMBO J 1993;12:3879–91
   PubMed Web of Science ®Google Scholar
• You X, Wu Y, Zeng Y, et al. Mycoplasma genitalium-derived lipid-associated membrane proteins induce activation of MAPKs, NF-kappaB and AP-1 in THP-1 cells. FEMS Immunol Med Microbiol 2008;52:228–36
   PubMed Web of Science ®Google Scholar
• Kida Y, Kobayashi M, Suzuki T, et al. Interleukin-1 stimulates cytokines, prostaglandin E2 and matrix metalloproteinase-1 production via activation of MAPK/AP-1 and NF-kappaB in human gingival fibroblasts. Cytokine 2005;29:159–68
   PubMed Web of Science ®Google Scholar
• Kim JH, Song AR, Sohn HJ, et al. IL-1beta and IL-6 activate inflammatory responses of astrocytes against Naegleria fowleri infection via the modulation of MAPKs and AP-1. Parasite Immunol 2013;35:120–8
   PubMed Web of Science ®Google Scholar
• Dandona P, Ghanim H, Bandyopadhyay A, et al. Insulin suppresses endotoxin-induced oxidative, nitrosative, and inflammatory stress in humans. Diabetes Care 2010;33:2416–23
   PubMed Web of Science ®Google Scholar
• Agwunobi AO, Reid C, Maycock P, et al. Insulin resistance and substrate utilization in human endotoxemia. J Clin Endocrinol Metab 2000;85:3770–8
   PubMed Web of Science ®Google Scholar
• Mehta NN, McGillicuddy FC, Anderson PD, et al. Experimental endotoxemia induces adipose inflammation and insulin resistance in humans. Diabetes 2009;59:172–81
   PubMed Web of Science ®Google Scholar
• Samuel VT, Shulman GI. Mechanisms for insulin resistance: common threads and missing links. Cell 2012;148:852–71
   PubMed Web of Science ®Google Scholar
• Nakatani Y, Kaneto H, Kawamori D, et al. Modulation of the JNK pathway in liver affects insulin resistance status. J Biol Chem 2004;279:45803–9
   PubMed Web of Science ®Google Scholar
• Kaneto H, Nakatani Y, Miyatsuka T, et al. Possible novel therapy for diabetes with cell-permeable JNK-inhibitory peptide. Nat Med 2004;10:1128–32
   PubMed Web of Science ®Google Scholar
• Hirosumi J, Tuncman G, Chang L, et al. A central role for JNK in obesity and insulin resistance. Nature 2002;420:333–6
   PubMed Web of Science ®Google Scholar
• Kim JK, Kim YJ, Fillmore JJ, et al. Prevention of fat-induced insulin resistance by salicylate. J Clin Invest 2001;108:437–46
   PubMed Web of Science ®Google Scholar
• Gao Z, Hwang D, Bataille F, et al. Serine phosphorylation of insulin receptor substrate 1 by inhibitor kappa B kinase complex. J Biol Chem 2002;277:48115–21
   PubMed Web of Science ®Google Scholar
• Yuan M, Konstantopoulos N, Lee J, et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 2001;293:1673–7
   PubMed Web of Science ®Google Scholar
• Jager J, Gremeaux T, Cormont M, et al. Interleukin-1beta-induced insulin resistance in adipocytes through down-regulation of insulin receptor substrate-1 expression. Endocrinology 2007;148:241–51
   PubMed Web of Science ®Google Scholar
• Aguirre V, Uchida T, Yenush L, et al. The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307). J Biol Chem 2000;275:9047–54
   PubMed Web of Science ®Google Scholar
• de Alvaro C, Teruel T, Hernandez R, Lorenzo M. Tumor necrosis factor alpha produces insulin resistance in skeletal muscle by activation of inhibitor kappaB kinase in a p38 MAPK-dependent manner. J Biol Chem 2004;279:17070–8
   PubMed Web of Science ®Google Scholar
• Cai D, Yuan M, Frantz DF, et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 2005;11:183–90
   PubMed Web of Science ®Google Scholar